ID   RPMI-8322
AC   CVCL_C542
SY   RPMI 8322; RPMI8322; Roswell Park Memorial Institute 8322; M-5; M5
DR   BTO; BTO:0005710
DR   Cosmic; 1054846
DR   Cosmic; 1507607
DR   Cosmic; 2233667
DR   Wikidata; Q54951269
RX   DOI=10.1093/jnci/59.2.301;
RX   PubMed=72600;
RX   PubMed=77569;
RX   PubMed=944091;
RX   PubMed=1127734;
RX   PubMed=1832891;
RX   PubMed=2423348;
RX   PubMed=8845476;
RX   PubMed=17308088;
CC   Doubling time: 38 hours (PubMed=1127734).
CC   HLA typing: A*02,09; B*07,w05 (PubMed=77569).
CC   Misspelling: RPMI8332; Cosmic=1054846; PubMed=17308088.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_ZY44 ! RPMI-7022
OI   CVCL_LH91 ! RPMI-7711
OI   CVCL_LH87 ! RPMI-7821
OI   CVCL_T323 ! RPMI-8252
OI   CVCL_U115 ! RPMI-8342
OI   CVCL_X375 ! RPMI-8362
OI   CVCL_X376 ! RPMI-8372
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-09-24; Version: 18
//
RX   DOI=10.1093/jnci/59.2.301;
RA   Quinn L.A., Woods L.K., Merrick S.B., Arabasz N.M., Moore G.E.;
RT   "Cytogenetic analysis of twelve human malignant melanoma cell lines.";
RL   J. Natl. Cancer Inst. 59:301-307(1977).
//
RX   PubMed=72600;
RA   Sharma B.;
RT   "In vitro immunization against human tumor cells with tumor cell
RT   fractions.";
RL   Cancer Res. 37:4660-4668(1977).
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=944091;
RA   McCulloch P.B., Dent P.B., Hayes P.R., Liao S.-K.;
RT   "Common and individually specific chromosomal characteristics of
RT   cultured human melanoma.";
RL   Cancer Res. 36:398-404(1976).
//
RX   PubMed=1127734; DOI=10.1093/jnci/54.5.1037;
RA   Liao S.-K., Dent P.B., McCulloch P.B.;
RT   "Characterization of human maligant melanoma cell lines. I. Morphology
RT   and growth characteristics in culture.";
RL   J. Natl. Cancer Inst. 54:1037-1044(1975).
//
RX   PubMed=1832891; DOI=10.1016/0277-5379(91)90277-K;
RA   Hansson J., Fichtinger-Schepman A.M.J., Edgren M.R., Ringborg U.;
RT   "Comparative study of two human melanoma cell lines with different
RT   sensitivities to mustine and cisplatin.";
RL   Eur. J. Cancer 27:1039-1045(1991).
//
RX   PubMed=2423348; DOI=10.1016/0014-4827(86)90037-6;
RA   Trejdosiewicz L.K., Southgate J., Kemshead J.T., Hodges G.M.;
RT   "Phenotypic analysis of cultured melanoma cells. Expression of
RT   cytokeratin-type intermediate filaments by the M5 human melanoma cell
RT   line.";
RL   Exp. Cell Res. 164:388-398(1986).
//
RX   PubMed=8845476; DOI=10.1097/00001813-199510000-00005;
RA   Zhao R., Rabo Y.B., Egyhazi Brage S., Andersson A., Edgren M.R.,
RA   Linder S., Hansson J.;
RT   "Apoptosis and c-jun induction by cisplatin in a human melanoma cell
RT   line and a drug-resistant daughter cell line.";
RL   Anticancer Drugs 6:657-668(1995).
//
RX   PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311;
RA   Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M.,
RA   Torrice C., Hao H.-L., Penland S., Arbiser J.L., Scott G.A., Zhou T.,
RA   Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L.,
RA   Sharpless N.E.;
RT   "Lack of extracellular signal-regulated kinase mitogen-activated
RT   protein kinase signaling shows a new type of melanoma.";
RL   Cancer Res. 67:1502-1512(2007).
//